[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?].
Lavelle
F
F
Rhône-Poulenc Rorer SA, Centre de recherche de Vitry-Alfortville, Vitry-sur-Seine, France.
D000818:Animals; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000737:chemistry; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011799:Quinazolines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D019311:Staurosporine / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D011799:Quinazolines; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D019311:Staurosporine